Molecular Formula | C54 H69 N11 O10 S2 |
Molar Mass | 1096.32 |
Density | 1.40±0.1 g/cm3(Predicted) |
Boling Point | 1508.2±65.0 °C(Predicted) |
pKa | 9.90±0.15(Predicted) |
Storage Condition | Keep in dark place,Sealed in dry,Store in freezer, under -20°C |
WGK Germany | 3 |
Overview | lanreotide is a drug used in the treatment of acromegaly and syndromes caused by neuroendocrine tumors. It is similar to octreotide and is a long-acting somatostatin analog. The drug is manufactured by the company Ipson and sold under the trade name of somadulin. The drug was approved for marketing in China on March 14, 2002. |
Use | lanreotide can be used in biological studies for statistical class alarm of furans, phenols, nitroso aromatics and thiobenzenes. Can be used for polypeptide synthesis. |
scientific research | since 2009, studies on the inhibition of polycystic liver by somatostatin have been published, so far there have been more than 17, of which there are about 7 to 8 studies of lanreotide, researchers from the Netherlands and Belgium, the United States also studied. on April 22, 2019, the department of Gastroenterology at the University Medical Center in radburg, the Netherlands, published the results of an updated clinical trial of lanreotide (Gastroenterology 2019 Apr 22). The purpose of this test is to test whether lanreotide can alleviate the growth of cysts in polycystic liver. A total of 120 patients with autosomal dominant polycystic kidney disease were enrolled in the 305-week trial, of whom 175 had a polycystic liver and liver volume of more than 2000 on MRI. Ninety-five of the 175 patients received subcutaneous injections of 120 mg of lanreotide every four weeks. after 120 weeks, the patients in the group receiving lanreotide had a 1.99% decrease in liver volume, whereas the control group had a 3.92% increase in liver volume, lanreotide reduced liver volume by 5.91%. Four months after the last injection of lanreotide, the growth of the liver volume was still reduced by 7.18% compared to the control group. currently, lanreotide is not used for the treatment of polycystic liver, and it is still in clinical trials. |
biological activity | Lanreotide (Laromustine, Angiopeptin, BIM 23014, Dermopeptin, Ipstyl, ITM-014, Somatulina, Somatuline, Lanreotidum) it is an analog of the native somatostatin peptide and is a physiological inhibitor of growth hormone (GH). Lanreotide also has anti-tumor effects. |
Target | Value |